Modelling group
at the Department of Medical Biometry, University of Tübingen

français deutsch
About us

Research
Influenza
Emerging diseases
Smallpox
Measles
Poliomyelitis
Malaria
Onchocerciasis
Filariases
Leishmaniasis
Haemophilus
Pneumococci
  Introduction
  EU project PNC-EURO
  Useful links
Others

Methods

Publications

Public Relations

Impressum

Pneumococci project

<i>Streptococcus pneumoniae</i>
Streptococcus pneumoniae ( journal MED)
Pneumococci
  EU project PNC-EURO
  Useful links
<i>Streptococcus pneumoniae</i> (cross-section)
Source: National Foundation for Infectious Diseases

There are at least 90 different serotypes of Pneumococcus, which strongly differ in their prevalence, incidence and virulence. As so far little is known about the interaction between different serotypes, it is difficult to predict the effects of a wide-spread use of the newly developed vaccines. Because of cross-immunity, vaccination may also effect the transmission of serotypes which are not included in the vaccine. Wide-spread vaccination may lead to a decline in all serotypes covered by the vaccine or vulnerable to cross-reacting antibodies, but this may also lead to undesired side effects. Some other serotypes may be rare now because they are constantly outcompeted by the more prevalent types. If that is the case, any reduction in the prevalence of one serotype may completely change the frequencies of all other serotypes. It is intrinsically different to determine whether rare serotypes are more or less pathogenic than the more prevalent ones. In the worst possible case, wide-spread vaccination may indirectly favor the spread of yet rare but highly pathogenic serotypes.
Responsible for this page: Prof. Dr. M. Eichner
Webmaster: Prof. Dr. M. Eichner (last change of this page on 13 July 2009)
Disclaimer: Eberhard-Karls-University Tübingen, Tübingen University Hospital, the Department for Medical Biometry (IMB), and the authors of this page disclaim all liability for the content of any page referenced by hyper-link from this page

You are the  th visitor of our pages.